For patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, this frequent complication occurs in roughly 30% of patients even at the time of initial diagnosis, and in about 60% of patients over the course of first-line therapy (Guérin et al., 2015; Johung et al., 2016). Here, ALK is linked to non-small cell lung carcinoma.